Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy

Hee Dong Han,1,* Yeongseon Byeon,1,* Tae Heung Kang,1 In Duk Jung,1 Jeong-Won Lee,2 Byung Cheol Shin,3 Young Joo Lee,4 Anil K Sood,5–7 Yeong-Min Park1 1Department of Immunology, School of Medicine, Konkuk University, Chungwondaero, Chungju-Si, Chungcheongbuk-Do, 2Department of Obstetrics...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Han HD, Byeon YS, Kang TH, Jung ID, Lee JW, Shin BC, Lee YJ, Sood AK, Park YM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	dendritic cell immunotherapy nanoparticles cancer Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/90131cfb68714478bddecf9ebb19a0bd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:90131cfb68714478bddecf9ebb19a0bd
record_format	dspace
spelling	oai:doaj.org-article:90131cfb68714478bddecf9ebb19a0bd2021-12-02T07:46:15ZToll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy1178-2013https://doaj.org/article/90131cfb68714478bddecf9ebb19a0bd2016-11-01T00:00:00Zhttps://www.dovepress.com/toll-like-receptor-3-induced-immune-response-by-polydl-lactide-co-glyc-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Hee Dong Han,1,* Yeongseon Byeon,1,* Tae Heung Kang,1 In Duk Jung,1 Jeong-Won Lee,2 Byung Cheol Shin,3 Young Joo Lee,4 Anil K Sood,5–7 Yeong-Min Park1 1Department of Immunology, School of Medicine, Konkuk University, Chungwondaero, Chungju-Si, Chungcheongbuk-Do, 2Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 3Bio/Drug Discovery Division, Korea Research Institute of Chemical Technology, Yuseong-gu, Daejeon, 4Department of Bioscience and Biotechnology, Sejong University, Kwang-Jin-Gu, Seoul, South Korea; 5Department of Gynecologic Oncology and Reproductive Medicine, 6Department of Cancer Biology, 7Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, TX, USA *These authors contributed equally to this work Abstract: Dendritic cells (DCs) are potent professional antigen-presenting cells that are capable of initiating a primary immune response and activating T cells, and they play a pivotal role in the immune responses of the host to cancer. Prior to antigen presentation, efficient antigen and adjuvant uptake by DCs is necessary to induce their maturation and cytokine generation. Nanoparticles (NPs) are capable of intracellular delivery of both antigen and adjuvant to DCs. Here, we developed an advanced poly(D,L-lactide-co-glycolide) (PLGA)-NP encapsulating both ovalbumin (OVA) as a model antigen and polyinosinic-polycytidylic acid sodium salt (Toll-like receptor 3 ligand) as an adjuvant to increase intracellular delivery and promote DC maturation. The PLGA-NPs were taken up by DCs, and their uptake greatly facilitated major histocompatibility class I antigen presentation in vitro. Moreover, vaccination with PLGA-NP-treated DCs led to the generation of ovalbumin-specific CD8+ T cells, and the resulting antitumor efficacy was significantly increased in EG.7 and TC-1 tumor-bearing mice compared to control mice (P<0.01). Taken together, these findings demonstrated that the PLGA-NP platform may be an effective method for delivering tumor-specific antigens or adjuvants to DCs. Keywords: cancer immunotherapy, PLGA nanoparticles, antigen deliveryHan HDByeon YSKang THJung IDLee JWShin BCLee YJSood AKPark YMDove Medical Pressarticledendritic cellimmunotherapynanoparticlescancerMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 11, Pp 5729-5742 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	dendritic cell immunotherapy nanoparticles cancer Medicine (General) R5-920
spellingShingle	dendritic cell immunotherapy nanoparticles cancer Medicine (General) R5-920 Han HD Byeon YS Kang TH Jung ID Lee JW Shin BC Lee YJ Sood AK Park YM Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy
description	Hee Dong Han,1,* Yeongseon Byeon,1,* Tae Heung Kang,1 In Duk Jung,1 Jeong-Won Lee,2 Byung Cheol Shin,3 Young Joo Lee,4 Anil K Sood,5–7 Yeong-Min Park1 1Department of Immunology, School of Medicine, Konkuk University, Chungwondaero, Chungju-Si, Chungcheongbuk-Do, 2Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 3Bio/Drug Discovery Division, Korea Research Institute of Chemical Technology, Yuseong-gu, Daejeon, 4Department of Bioscience and Biotechnology, Sejong University, Kwang-Jin-Gu, Seoul, South Korea; 5Department of Gynecologic Oncology and Reproductive Medicine, 6Department of Cancer Biology, 7Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, TX, USA *These authors contributed equally to this work Abstract: Dendritic cells (DCs) are potent professional antigen-presenting cells that are capable of initiating a primary immune response and activating T cells, and they play a pivotal role in the immune responses of the host to cancer. Prior to antigen presentation, efficient antigen and adjuvant uptake by DCs is necessary to induce their maturation and cytokine generation. Nanoparticles (NPs) are capable of intracellular delivery of both antigen and adjuvant to DCs. Here, we developed an advanced poly(D,L-lactide-co-glycolide) (PLGA)-NP encapsulating both ovalbumin (OVA) as a model antigen and polyinosinic-polycytidylic acid sodium salt (Toll-like receptor 3 ligand) as an adjuvant to increase intracellular delivery and promote DC maturation. The PLGA-NPs were taken up by DCs, and their uptake greatly facilitated major histocompatibility class I antigen presentation in vitro. Moreover, vaccination with PLGA-NP-treated DCs led to the generation of ovalbumin-specific CD8+ T cells, and the resulting antitumor efficacy was significantly increased in EG.7 and TC-1 tumor-bearing mice compared to control mice (P<0.01). Taken together, these findings demonstrated that the PLGA-NP platform may be an effective method for delivering tumor-specific antigens or adjuvants to DCs. Keywords: cancer immunotherapy, PLGA nanoparticles, antigen delivery
format	article
author	Han HD Byeon YS Kang TH Jung ID Lee JW Shin BC Lee YJ Sood AK Park YM
author_facet	Han HD Byeon YS Kang TH Jung ID Lee JW Shin BC Lee YJ Sood AK Park YM
author_sort	Han HD
title	Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy
title_short	Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy
title_full	Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy
title_fullStr	Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy
title_full_unstemmed	Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy
title_sort	toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/90131cfb68714478bddecf9ebb19a0bd
work_keys_str_mv	AT hanhd tolllikereceptor3inducedimmuneresponsebypolydllactidecoglycolidenanoparticlesfordendriticcellbasedcancerimmunotherapy AT byeonys tolllikereceptor3inducedimmuneresponsebypolydllactidecoglycolidenanoparticlesfordendriticcellbasedcancerimmunotherapy AT kangth tolllikereceptor3inducedimmuneresponsebypolydllactidecoglycolidenanoparticlesfordendriticcellbasedcancerimmunotherapy AT jungid tolllikereceptor3inducedimmuneresponsebypolydllactidecoglycolidenanoparticlesfordendriticcellbasedcancerimmunotherapy AT leejw tolllikereceptor3inducedimmuneresponsebypolydllactidecoglycolidenanoparticlesfordendriticcellbasedcancerimmunotherapy AT shinbc tolllikereceptor3inducedimmuneresponsebypolydllactidecoglycolidenanoparticlesfordendriticcellbasedcancerimmunotherapy AT leeyj tolllikereceptor3inducedimmuneresponsebypolydllactidecoglycolidenanoparticlesfordendriticcellbasedcancerimmunotherapy AT soodak tolllikereceptor3inducedimmuneresponsebypolydllactidecoglycolidenanoparticlesfordendriticcellbasedcancerimmunotherapy AT parkym tolllikereceptor3inducedimmuneresponsebypolydllactidecoglycolidenanoparticlesfordendriticcellbasedcancerimmunotherapy
_version_	1718399170669182976

Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy

Ejemplares similares